Gamma Vaccines acquires IP to develop NDV vaccine

Gamma Vaccines has signed a deed of assignment with the University of Adelaide for the rights to commercialise vaccines for NDV (Newcastle disease), either alone or in combination with our other proprietary vaccines.

Share this post

18/03/2025
Gamma Vaccines Changes its Status to a Public Company Limited by Shares
Gamma Vaccines announces that it has changed its status from a Private Company limited by shares to a…

Read article
12/09/2024
Gamma vaccines signs international collaboration agreement.
Gamma vaccines has entered a collaboration agreement with Capricorn Technologies GmBH (Austria) and Aptum Adjuvants Ltd (UK) to…

Read article
05/09/2024
Gamma Vaccines files patent on combination vaccines
Gamma Vaccines has filed a patent application on combination vaccines that incorporate our photon-inactivated vaccine with other immunogens,…

Read article

View All Articles

Gamma Vaccines acquires IP to develop NDV vaccine

Share this post

Related Articles

Gamma Vaccines Changes its Status to a Public Company Limited by Shares

Gamma vaccines signs international collaboration agreement.

Gamma Vaccines files patent on combination vaccines